Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial

被引:175
作者
Toma, Mustafa [1 ]
Buller, Christopher E. [2 ]
Westerhout, Cynthia M. [1 ]
Fu, Yuling [1 ]
O'Neill, William W. [3 ]
Holmes, David R., Jr. [4 ]
Hamm, Christian W. [5 ]
Granger, Christopher B. [6 ]
Armstrong, Paul W. [1 ]
机构
[1] Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB T6G 2H7, Canada
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[4] Mayo Clin, Rochester, MN USA
[5] Kerckhoff Heart Ctr, Bad Nauheim, Germany
[6] Duke Clin Res Inst, Durham, NC USA
关键词
Non-culprit coronary artery; Primary percutaneous coronary intervention; Myocardial infarction; PRIMARY ANGIOPLASTY; REPERFUSION; DISEASE; VESSEL;
D O I
10.1093/eurheartj/ehq129
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To examine the incidence of and propensity for non-culprit interventions performed at the time of the primary percutaneous coronary intervention (PCI) and its association with 90-day outcomes. We examined the incidence, propensity for, and associated 90-day outcomes following non-culprit interventions performed at the time of primary PCI among ST-elevation myocardial infarction patients with multi-vessel coronary artery disease (MVD). Of the 5373 patients who underwent primary PCI in the APEX-AMI trial, 2201 had MVD. Of those, 217 (9.9%) underwent non-infarct-related arteries (IRA) PCI, whereas 1984 (90.1%) underwent PCI of the IRA alone. Ninety-day death and death/CHF/shock were higher in the non-IRA group compared with the IRA-only PCI group (12.5 vs. 5.6%, P (log-rank) < 0.001 and 17.4 vs. 12.0%, P (log-rank) = 0.020, respectively). After adjusting for patient and procedural characteristics as well as propensity for performing non-IRA PCI, this procedure remained independently associated with an increased hazard of 90-day mortality [adjusted hazard ratio 2.44, 95% CI (1.55-3.83), P < 0.001]. Non-culprit coronary interventions were performed at the time of primary PCI in 10% of MVD patients and were significantly associated with increased mortality. Our data support current guideline recommendations discouraging the performance of such procedures in stable primary PCI patients. Prospective randomized study of this issue may be warranted.
引用
收藏
页码:1701 / 1707
页数:7
相关论文
共 50 条
  • [1] Age and Outcomes in ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention Findings From the APEX-AMI Trial
    Gharacholou, S. Michael
    Lopes, Renato D.
    Alexander, Karen P.
    Mehta, Rajendra H.
    Stebbins, Amanda L.
    Pieper, Karen S.
    James, Stefan K.
    Armstrong, Paul W.
    Granger, Christopher B.
    ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (06) : 559 - 567
  • [2] Transfer Times and Outcomes in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Interhospital Transfer for Primary Percutaneous Coronary Intervention APEX-AMI Insights
    van Diepen, Sean
    Widimsky, Petr
    Lopes, Renato D.
    White, Kyle R.
    Weaver, W. Douglas
    Van de Werf, Frans
    Ardissino, Diego
    van't Hof, Arnoud W. J.
    Armstrong, Paul W.
    Granger, Christopher B.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2012, 5 (04): : 437 - 444
  • [3] Major adverse cardiovascular events while awaiting staged non-culprit percutaneous coronary intervention after ST-segment elevation myocardial infarction
    McCutcheon, Keir
    Triantafyllis, Andreas S.
    Marynissen, Thomas
    Adriaenssens, Tom
    Bennett, Johan
    Dubois, Christophe
    Sinnaeve, Peter R.
    Desmet, Walter
    ACTA CARDIOLOGICA, 2019, 74 (01) : 60 - 64
  • [4] Percutaneous coronary intervention in the elderly with ST-segment elevation myocardial infarction
    Gao, Lei
    Hu, Xin
    Liu, Yu-Qi
    Xue, Qiao
    Feng, Quan-Zhou
    CLINICAL INTERVENTIONS IN AGING, 2014, 9 : 1241 - 1246
  • [5] Aborted myocardial infarction after primary percutaneous coronary intervention: Magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
    Patel, Manesh R.
    Westerhout, Cynthia M.
    Granger, Christopher B.
    Brener, Sorin J.
    Fu, Yuling
    Siha, Hany
    Kim, Raymond J.
    Armstrong, Paul W.
    AMERICAN HEART JOURNAL, 2013, 165 (02) : 226 - 233
  • [6] Percutaneous coronary intervention strategies in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease
    Thomas, Michael P.
    Bates, Eric R.
    CURRENT OPINION IN CARDIOLOGY, 2017, 32 (06) : 755 - 760
  • [7] Improving Adjunctive Pharmacotherapy for Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: Beyond the HORIZONS-AMI Trial
    Kereiakes, Dean J.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2009, 10 (02) : 72 - 82
  • [8] ST-segment resolution after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction
    Ndrepepa, Gjin
    Alger, Patricia
    Kufner, Sebastian
    Mehilli, Julinda
    Schoemig, Albert
    Kastrati, Adnan
    CARDIOLOGY JOURNAL, 2012, 19 (01) : 61 - 69
  • [9] Impact of thrombus aspiration during primary percutaneous coronary intervention on mortality in ST-segment elevation myocardial infarction
    Noman, Awsan
    Egred, Mohaned
    Bagnall, Alan
    Spyridopoulos, Ioakim
    Jamieson, Sheila
    Ahmed, Javed
    EUROPEAN HEART JOURNAL, 2012, 33 (24) : 3054 - 3061
  • [10] Comparison of the cost in percutaneous coronary intervention between ST-segment elevation myocardial infarction vs. non-ST-segment elevation myocardial infarction
    Murakami, Tsukasa
    Sakakura, Kenichi
    Taniguchi, Yousuke
    Yamamoto, Kei
    Tsukui, Takunori
    Seguchi, Masaru
    Jinnouchi, Hiroyuki
    Wada, Hiroshi
    Fujita, Hideo
    CARDIOVASCULAR INTERVENTION AND THERAPEUTICS, 2022, 37 (02) : 293 - 303